Category: Zimmer Holdings
Zimmer Holdings says its 3rd-quarter earnings beat expectations and narrows its sales and earnings guidance for the rest of the year.
Zimmer's (NYSE:ZMH) 3rd-quarter earnings came in ahead of expectations on strong performances from its core knee and hip implant businesses.
Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit
, Becton Dickinson & Co.
, DePuy Synthes
, GenCell Biosystems
, Johnson & Johnson
, Kimberly-Clark Worldwide Inc.
, MAKO Surgical Corp.
, Stryker Corp.
, Valeant Pharmaceuticals
, 3M Corp.
, Allergan Inc.
More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.
Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic, Covidien name peripherals biz transition team; Medtronic is still in on Covidien buyout; The Street cheers changes to the Medtronic, Covidien deal; Zimmer adds Harvard spinout Etex Corp.; EU to extend Zimmer, Biomet probe
European anti-trust regulators are extending their probe into the proposed $13 billion merger of orthopedics rivals Zimmer and Biomet.
UPDATED Oct. 2, 2013, with comment from Zimmer.
Zimmer acquires Etex Corp. and its line of bone biomaterials for an unspecified amount.
Zimmer (NYSE:ZMH) said yesterday that it paid an unspecified amount for Etex Corp. and the bone biomaterials it's developing in Cambridge, Mass.
Zimmer and Biomet provide updates following the 2nd in a series of "Integration Summits" where company leadership is fleshing out the details of their $13 billion merger.
Leadership at Zimmer (NYSE:ZMH) and Biomet have been on merger overdrive in recent weeks, holding summits and hosting presentations as the companies navigate the tricky business of a $13 billion merger.